CUSIP: 29604W108
Q1 2023 13F Holders as of 31 Mar 2023
-
Type / Class
-
Equity / SPONSORED ADR
-
Total 13F shares
-
373,376
-
Share change
-
-368,586
-
Total reported value
-
$374,405
-
Put/Call ratio
-
25%
-
Price per share
-
$0.98
-
Number of holders
-
9
-
Value change
-
+$20,262
-
Number of buys
-
3
-
Number of sells
-
5
Quarterly Holders Quick Answers
What is CUSIP 29604W108?
CUSIP 29604W108 identifies PHXM - ERYTECH PHARMA - SPONSORED ADR in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q2 2023
-
Previous quarter:
Q4 2022
Recent filing periods for CUSIP 29604W108:
Institutional Holders of ERYTECH PHARMA - SPONSORED ADR (PHXM) as of Q1 2023
As of 31 Mar 2023,
ERYTECH PHARMA - SPONSORED ADR (PHXM) was held by
9 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
373,376 shares.
The largest 9 holders included
Ikarian Capital, LLC, MILLENNIUM MANAGEMENT LLC, Vanguard Personalized Indexing Management, LLC, Mariner, LLC, Virtu Financial LLC, CITADEL ADVISORS LLC, GROUP ONE TRADING, L.P., Asset Dedication, LLC, and UBS Group AG.
This page lists
9
institutional shareholders reporting positions in this security
for the Q1 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.